1deKoning L,Merchant AT,Pogue J,et al. Waist circumferenceand waist-to-hip ratio as predictors of cardiovascular events : meta-re-gression analysis of prospective studies. Eur Heart J 2007 ; 28 (7 ):850-856.
2deKoning L,Merchant AT,Pogue J,et al. Waist circumferenceand waist-to-hip ratio as predictors of cardiovascular events : meta-re-gression analysis of prospective studies. Eur Heart J 2007 ; 28 (7):850-856.
3Malm-Erjefalt,Ekblom M,Brondsted L,et al. A randomised,double-blind, cross-over trial investigating the effect of liraglutide onthe absorption pharmacokinetics of concomitantly administered oraldrugs in healthy subjects. Diabetes 2008 ;57 (Suppl. 1) :434.
4Nauck M, Pratley R, Brett J,et al. Adding liraglutide to exist-ing therapy produces greater improvement in glycemic control : evi-dence from a meta-analysis. Diabetes 2009 ;58( Suppl. 1) : A122.
5Monami M, Dicembrini I, Marchionni N,et al. Effects of glu-cagon-like peptide-1 receptor agonists on body weight : a meta-analy-sis. Exp Diabetes Res 2012 ; 10 :672658-672666.
6Pantalone KM,Faiman C. Liraglutide effective in the severelyinsulin-resistant patient with type 2 diabetes requiring U-500 insulin : acase report. Diabetes Technol Ther 2013 ;15(4) :342-343.
7YuyaFujishima, Norikazu Maeda, Kana Inoue, et al. Efficacyof liraglutide,a glucagon-like peptide-1 ( GLP-1) analogue,on bodyweight,eating behavior,and glycemic control,in Japanese obese type 2diabetes. Cardiovascular Diabetology 2012;9( 11) :107-115.
8Wing RR, Lang W, Wadden TA, et al. Look AHEAD Re-search Group : Benefits of modest weight loss in improving cardiovas-cular risk factors in overweight and obese individuals with type 2 dia-betes. Diabetes Care 2011 ;34(7) : 1481-1486.
9Kawashima S, Matsuoka TA, Kaneto H, et al. Effect of alo-gliptin, pioglitazone and glargine on pancreatic p-cells in diabetic db/db mice. BiocheraBiophys Res Comxnun 2011 ;404( 1) :534 - 540.
1DeOre K,Greig NH,Holloway HW,et al.The effects of GLP-1 on insulin release in young and old rats in the fasting state and during an intravenous glucose tolerance test.J Gerontol A Biol Sci Med Sci,1997,52:245-249.
2Yang G,Li L,Tang Y,et al.Short-term pioglitazone treatment prevents free fatty acid-induced hepatic insulin resistance in normal rats:possible role of the resistin and adiponectin.Biochem Biophys Res Commun,2006,339:1190-1196.
3Samuel VT,Liu ZX,Qu X,et al.Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease.J Biol Chem,2004,279:32345-32353.
4Hansen I,Deacon CF,Orskov C,et al.Glucagon-like peptide-1 (7-36) amide is transformed to glucagon-like peptide-1-(9-36) amide by dipeptidyl peptidase Ⅳ in the capillaries supplying the Ⅰ cells of porcine intestine.Endocrinology,1999,140:5356.
5Liu X,Harada N,Yamane S,et al.Effects of long-term dipeptidyl peptidase-Ⅳ inhibition on body composition and glucose tolerance in high fat diet-fed mice.Life Sci,2009,84:876-881.
6Vilsbφll T,Zdravkovic M,Le-Thi T,et al.Liraglutide,a long-acting human glucagon-like peptide-1 analog,given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes.Diabetes Care 2007,30:1608-1610.
7Kirsten R,Vossl PV,Carsten F,et al.Liraglutide,a long-acting glucagon-like peptide-1 analog,reduces body weight and food intake in obese candy-fed rats,whereas a dipeptidyl peptidase-Ⅳ inhibitor,vildagliptin,does not.Diabetes,2007,56:8-15.
